Jiangsu Dongke Kangde Pharmaceutical Co., Ltd.

The main purpose of the study is to use the bilastine tablets (trade name: ILAXTEN, 20 mg) licensed by Menarini International Operations Luxembourg S.A. as the reference preparation and the bilastine tablets held by Jiangsu Dongke Kangde Pharmaceutical Co., Ltd. as the test preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions through a single-center, randomized, open, single-dose, two-preparation, two-sequence, two-cycle, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Main purpose: According to the relevant provisions of bioequivalence test, azithromycin dry suspension (trade name: Xishumei®, specification: 0.1g/bag) produced by Pfizer Pharmaceuticals Co., Ltd. was selected as the reference preparation, and the test preparation azithromycin dry suspension (specification: 0.1g/bag) produced by Jiangsu Dongke Kangde Pharmaceutical Co., Ltd. was subjected to human bioequivalence test on fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to compare the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose: To observe the safety of oral administration of the test preparation azithromycin dry suspension (specification: 0.1g/bag) and the reference preparation azithromycin dry suspension (trade name: Xishumei®, specification: 0.1g/bag) in healthy subjects.

Main study purpose: According to the relevant provisions of bioequivalence test, lenvatinib mesylate capsules (trade name: LENVIMA®, specification: 4 mg/capsule) with Eisai Europe Ltd. as the licensee were selected as the reference preparation, and the test preparation lenvatinib mesylate capsules (specification: 4 mg/capsule) produced by Jiangsu Huayang Pharmaceutical Co., Ltd. and provided by Jiangsu Dongke Kangde Pharmaceutical Co., Ltd. were subjected to human bioequivalence test for fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation lenvatinib mesylate capsules (specification: 4 mg/capsule) and the reference preparation lenvatinib mesylate capsules (trade name: LENVIMA®, specification: 4 mg/capsule) in healthy volunteers.